


Ifw

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 0112713-983	
In Re Application Of: Smith et al.					
Application No. 10/634,663	Filing Date August 5, 2003	Examiner Unknown	Customer No. 29200	Group Art Unit 1651	Confirmation No. 6356
Title: INVITRO CELL CULTURE EMPLOYING A FIBRIN NETWORK IN A FLEXIBLE GAS PERMEABLE CONTAINER					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0112713-983

In Re Application: Smith et al



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/634,663	August 5, 2003	Unknown	29200	1651	

INVITRO CELL CULTURE EMPLOYING A FIBRIN NETWORK IN A FLEXIBLE GAS CONTAINER

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on July 14, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Renee Street

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Dated: July 14, 2004

Signature

Robert M. Barrett (Reg. No. 30,142)
BELL, BOYD & LLOYD LLC
P. O. Box 1135
Chicago, Illinois 60690-1135
(312) 807-4204

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Smith et al.
Appl. No.: 10/634,663
Conf. No.: 6356
Filed: August 5, 2003
Title: INVITRO CELL CULTURE EMPLOYING A FIBRIN NETWORK IN A
FLEXIBLE GAS PERMEABLE CONTAINER
Art Unit: 1651
Examiner: Unknown
Docket No.: 0112713-983

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, be made during the course of examination of the above-identified application for United States patent. Pursuant to the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patents and patent applications are not included as this application was filed after June 30, 2003. However, copies of all other cited references are included with this form.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
4,140,162	February 20, 1979	Gajewski et al.
4,222,379	September 16, 1980	Smith
4,496,361	January 29, 1985	Kilkson
4,588,401	May 13, 1986	Kilkson
4,631,055	December 23, 1986	Redl et al.
4,910,147	March 20, 1990	Bacehowski et al.
4,939,151	July 3, 1990	Bacehowski et al.
4,978,336	December 18, 1990	Capozzi et al.
5,272,074	December 21, 1993	Rubens
5,324,647	June 28, 1994	Rubens et al.
5,912,177	June 15, 1999	Turner et al.

5,935,847	August 10, 1999	Smith et al.
5,989,215	December 23, 1999	Delmotte et al.
6,074,663	June 13, 2000	Delmotte et al.
6,297,046	October 2, 2001	Smith et al.
2002/0131933	September 19, 2002	Delmotte

OTHER DOCUMENTS

Tisseel Engineering Fibrin Matrix Technology, The Fibrin Network in Tissue Engineering, Harnessing the Morphogenic Potential Of Regenerating Tissues, Baxter Healthcare Corporation.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC


BY

Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204

Dated: July 14, 2004



**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

PTO Form 1449

Atty Docket No.
0112713-983

Application No.
10/634,663

Applicant
Smith et al.

Filing Date
August 5, 2003

Group
1651

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	4,140,162	February 20, 1979	Gajewski et al.			
	4,222,379	September 16, 1980	Smith			
	4,496,361	January 29, 1985	Kilkson			
	4,588,401	May 13, 1986	Kilkson			
	4,631,055	December 23, 1986	Redl et al.			
	4,910,147	March 20, 1990	Bacehowski et al.			
	4,939,151	July 3, 1990	Bacehowski et al.			
	4,978,336	December 18, 1990	Capozzi et al.			
	5,272,074	December 21, 1993	Rubens			
	5,324,647	June 28, 1994	Rubens et al.			
	5,912,177	June 15, 1999	Turner et al.			
	5,935,847	August 10, 1999	Smith et al.			
	5,989,215	December 23, 1999	Delmotte et al.			
	6,074,663	June 13, 2000	Delmotte et al.			
	6,297,046	October 2, 2001	Smith et al.			
	2002/0131933	September 19, 2002	Delmotte			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Tisseel Engineering Fibrin Matrix Technology, The Fibrin Network in Tissue Engineering, Harnessing the Morphogenic Potential Of Regenerating Tissues, Baxter Healthcare Corporation.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	